L
Description
Clinical-stage biopharmaceutical company founded in 2019 in Boston, Massachusetts, focused on restoring immune tolerance through TIM (T-cell immunoglobulin and mucin domain) agonists. Lead candidate LPX-TI641 is in Phase 1 clinical study for multiple sclerosis and other autoimmune diseases.